Global /China /Healthcare /Drug Manufacturers - General /300006

Chongqing Lummy Pharmaceutical Co., Ltd.

300006

• SHE: 300006 • Delayed

6.39CNY -0.8%

0.9442 USD

As of 14 June 2026, Chongqing Lummy Pharmaceutical Co., Ltd. has a market cap of $1.0B USD, ranking #10691 globally and #2998 in China. It ranks #954 in the Healthcare sector, and #355 in the Drug Manufacturers - General industry.

Global Rank

10691

Country Rank

2998

Sector Rank

954

Industry Rank

355

Key Stats

Market Cap

$1.0BUSD

6.8B CNY

Enterprise Value

$930.28MUSD

6.3B CNY

Revenue (TTM)

$112.09MUSD

759.5M CNY

EBITDA (TTM)

-$4.38MUSD

-29.64M CNY

Net Income (TTM)

-$20.06MUSD

-135.94M CNY

EBITDA Margin

-3.9%

Profit Margin

-18%

PS Ratio

9.0

PB Ratio

3.9

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Rongzhao Qiu open_in_new

Employees

973

Founded

1999

Website

cqlummy.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-0.8%	0.6%	27%	27%	39%	25%	98%	70%	-6.1%

News

Markets

Exchange	Ticker	Price	Quotes
Shenzhen Stock Exchange (SHE / SZSE) MIC: XSHE PRIMARY	300006 重庆市莱美医药有限公司 Class A ISIN: CNE100000H10 Shares Out.: Shares Outstanding: 1.056B¹ Shares Float: 888.582M² TV: TradingView: SZSE: 300006 SA: Stock Analysis: SHE: 300006 YF: Yahoo Finance: 300006.SZ GF: Google Finance: SHE: 300006 BA: Barron's: 300006 MS: Morningstar: XSHE: 300006	6.39 CNY	TV: TradingView: SZSE: 300006 SA: Stock Analysis: SHE: 300006 YF: Yahoo Finance: 300006.SZ GF: Google Finance: SHE: 300006 BA: Barron's: 300006 MS: Morningstar: XSHE: 300006

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Chongqing Lummy Pharmaceutical Co., Ltd.

Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. The company was founded in 1999 and is headquartered in Chongqing, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$53.85B 364.89B CNY 5K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.64B 336.36B CNY 5K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.52B 223.48B HKD 3K%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.8B 147.32B HKD 2K%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.51B 111.89B CNY 2K%	-	China
Akeso, Inc. SHEK: 9926	$16.01B 125.46B HKD 1K%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 76K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 54K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 36K%	97.4	United States
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 32K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 29K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 27K%	20.5	Switzerland

chevron_leftBack